Skip to main content
Clinical Trials/NL-OMON49536
NL-OMON49536
Completed
Not Applicable

Intervention study investigating the effect of a dietary intervention geared towards improved adherence to the Dutch dietary guidelines on the 10-year risk for recurrent vascular events (SMART risk score) in patients with cardiovascular diseases compared with usual care. - Dutch dietary guidelines for patients with cardiovascular diseases.

Wageningen Universiteit0 sites124 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Wageningen Universiteit
Enrollment
124
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
December 7, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Be categorised in the highest risk category of the guideline for
  • cardiovascular risk management 2019 (Tjin\-A\-Ton, J., \& Vrolijk, M., 2019\). This
  • includes patients with:
  • o Previously diagnosed cardiovascular disease, including acute coronary disease
  • syndrome, angina, coronary revascularization, TIA or stroke, symptomatic aortic
  • iliofemoral atherosclerosis, aortic aneurysm, intermittent claudication or
  • peripheral revascularization.
  • \- Aged 18 year or older.

Exclusion Criteria

  • \- Uses medication (e.g. metformine, sulfonylureumderivate, insulin or
  • DPP4\-inhibitors/GLP1\-agonists) for treatment of diabetes
  • \- a known hereditary form of cardiovascular diseases (e.g. Familial
  • hypercholesterolaemia)
  • \- chronic kidney disease in stage 4 or above (meaning an eGFR\<30\)
  • o In this case, patients should get dietary advise about their protein intake,
  • which is not in line with the general advise in our study
  • \- The patient has changes in one or more of the following medication in the
  • past two weeks: lipid\-lowering agents, blood pressure\-lowering agents,
  • glucose\-lowering agents and antithrombotics

Outcomes

Primary Outcomes

Not specified

Similar Trials